A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to know before stopping.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

The first oral pill for obstructive sleep apnea (OSA) could be around the corner after pharmaceutical company Apnimed Inc.

The US Food and Drug Administration (FDA) has instructed all GLP-1 drug-makers to update their warning labels to include the ...

Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...